obesity-congress-diabetes-congress-2018-posters

Page 64

O c t o b e r 1 5 - 1 6 , 2 0 1 8 | T o k y o , J a p a n

Obesity Congress 2018, Diabetes Congress 2018 & Vaccines Congress 2018

Biomedical Research

ISSN: 0976-1683

Volume 29

WORLD OBESITY CONGRESS

WORLD VACCINES AND IMMUNOLOGY CONGRESS

DIABETES AND ENDOCRINOLOGY

International Conference on

Joint Event on

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C5-014

PHASE III TRIAL FOR IMMUNOTHERAPY OF HIGH-GRADE CERVICAL

DYSPLASIA CAUSED BY HUMAN PAPILLOMAVIRUS

Mark L Bagarazzi

Inovio Pharmaceuticals, USA

GX-3100 is an immunotherapy designed using SynCon® approach to treat HPV-16 and HPV-18 infection and pre-cancerous

lesions of the cervix (phase 3) and vulva (phase 2). The immunogenicity and efficacy of VGX-3100 is enabled by the CEL-

LECTRA® electroporation delivery system. When VGX-3100 is delivered with the CELLECTRA® device it stimulates a specific

immune response to HPV-16 and HPV-18 E6 and E7, to clear the infection and eliminate pre-cancerous cells. In a randomized,

double-blind, placebo-controlled phase 2b study in 167 adult women with histologically documented HPV-16/18 cervical HSIL

(CIN2/3), treatment with VGX-3100 resulted in a statistically significantly greater decrease in cervical HSIL and clearance of HPV

infection vs. placebo. The most common side effect was injection site pain, and no serious adverse events were reported. The

VGX-3100 approach which utilizes the patient’s own immune system to clear HPV-16 and HPV-18 infection and pre-cancerous

lesions without the increased risks associated with surgery, such as loss of reproductive health and negative psychosocial im-

pacts is now being evaluated in a global phase three study. VGX-3100 has the potential to be the first approved treatment for HPV

infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions.